title: Changes in serum uric acid levels after allogeneic hematologic stem cell transplantation: A retrospective cohort study.
abstract: BACKGROUND
  Since cell turnover in the hematopoietic system constitutes a major source of uric acid (UA) production, we investigated whether hematopoietic stem cell transplantation (HSCT) is associated with significant changes in serum UA levels in patients with hematological disorders.
  
  
  METHODS
  Patients who underwent HSCT at our institution between 2001 and 2012 were retrospectively enrolled. Serum UA levels at 3 months before, 1 week before, and 3 months and 1 year after HSCT were examined.
  
  
  RESULTS
  Complete clinical and laboratory information including data regarding UA levels was available for 93 patients. At baseline, the mean UA level was 4.9±2.1 mg/dL, with an overall prevalence of hyperuricemia of 15% (defined as serum UA>6.8 mg/dL). Mean UA levels tended to be higher in patients with acute myeloid leukemia (4.8±2.0 mg/dL) and non-Hodgkin lymphoma (5.1±2.3 mg/dL) and lower in patients with aplastic anemia (mean, 4.2±1.8 mg/dL). UA levels dropped during myeloablative conditioning, reaching a nadir on the day of HSCT (3.27±1.4 mg/dL). Over the 3 months following HSCT, UA levels rose sharply (5.0±2.1 mg/dL) and remained stable up to 1 year after HSCT (5.5±1.6 mg/dL). UA levels in HSCT recipients at 12 months correlated with those of their respective graft donors (Pearson r=0.406,P=0.001).
  
  
  CONCLUSIONS
  HSCT is associated with significant changes in uric acid levels in patients with hematologic disorders.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
authors.forename: Sang Hyun
authors.initials: SH
authors.lastname: Joo
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Medical Research Institute, Seoul National University, Seoul, Korea.
authors.forename: Jin Kyun
authors.initials: JK
authors.lastname: Park
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
authors.forename: Eunyoung Emily
authors.initials: EE
authors.lastname: Lee
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Medical Research Institute, Seoul National University, Seoul, Korea.
authors.forename: Yeong Wook
authors.initials: YW
authors.lastname: Song
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.; Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
authors.forename: Sung-Soo
authors.initials: SS
authors.lastname: Yoon
keywords: Bone marrow; Hematopoietic stem cell transplantation; Uric acid